A profile of immune response to herpesvirus is associated with radiographic joint damage in rheumatoid arthritis

Arthritis Research and Therapy

Volumn 14, Issue 1, 2012, Pages

  Davis III, John M ^a   Knutson, Keith L ^b   Skinner, John A ^a   Strausbauch, Michael A ^a   Crowson, Cynthia S ^c   Therneau, Terry M ^c   Wettstein, Peter J ^a   Matteson, Eric L ^a,c   Gabriel, Sherine E ^a,c  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c Mayo Clinic   (United States)

Author keywords

Cytokines; Cytomegalovirus; Epstein barr virus; Immune responses; RA; Radiographic joint damage; Rheumatoid arthritis; T cells

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; METHOTREXATE; PREDNISONE; RITUXIMAB; CYTOKINE;

ADULT; AGE; ANTIBODY TITER; ARTICLE; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOMEGALOVIRUS; DISABILITY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; EPSTEIN BARR VIRUS; FEMALE; HERPES VIRUS; HUMAN; IMMUNE RESPONSE; JOINT DESTRUCTION; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NONHUMAN; PATHOGENICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; RHEUMATOID ARTHRITIS; SEROLOGY; SEX; SHARP VAN DER HEIJDE SCORE; STIMULUS; CELL CULTURE; HERPES VIRUS INFECTION; IMMUNOLOGY; JOINT; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; MULTIVARIATE ANALYSIS; PATHOLOGY; PRINCIPAL COMPONENT ANALYSIS; RADIOGRAPHY; T LYMPHOCYTE; VIROLOGY;

ARTHRITIS, RHEUMATOID; CELLS, CULTURED; CYTOKINES; CYTOMEGALOVIRUS; FEMALE; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; JOINTS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; T-LYMPHOCYTES;

EID: 84856346457     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3706     Document Type: Article

References (87)

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010, 376:1094-1108. 10.1016/S0140-6736(10)60826-4, 20870100.
2. Cope AP. T cells in rheumatoid arthritis. Arthritis Res Ther 2008, 10(Suppl 1):S1. 10.1186/ar2412, 2582808, 19007426.
3. Weyand CM. Immunopathologic aspects of rheumatoid arthritis: who is the conductor and who plays the immunologic instrument?. J Rheumatol Suppl 2007, 79:9-14.
4. van den Berg WB, van Lent PL, Joosten LA, Abdollahi-Roodsaz S, Koenders MI. Amplifying elements of arthritis and joint destruction. Ann Rheum Dis 2007, 66(Suppl 3):iii45-48. 2095284, 17934095.
5. Emery P, Breedveld F, van der Heijde D, Ferraccioli G, Dougados M, Robertson D, Pedersen R, Koenig AS, Freundlich B. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Arthritis Rheum 2010, 62:674-682. 10.1002/art.27268, 20187135.
6. van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, Tornero-Molina J, Wajdula J, Pedersen R, Fatenejad S. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006, 54:1063-1074. 10.1002/art.21655, 16572441.
7. Durnez A, Vanderschueren G, Lateur L, Westhovens R, Verschueren P. Effectiveness of initial treatment allocation based on expert opinion for prevention of rapid radiographic progression in daily practice of an early RA cohort. Ann Rheum Dis 2011, 70:634-637. 10.1136/ard.2010.135319, 21177296.
8. Vastesaeger N, Xu S, Aletaha D, St Clair EW, Smolen JS. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford) 2009, 48:1114-1121.
9. Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Seys PE, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis 2010, 69:1333-1337. 10.1136/ard.2009.121160, 20498212.
10. Bakker MF, Jacobs JW, Welsing PM, Vreugdenhil SA, van Booma-Frankfort C, Linn-Rasker SP, Ton E, Lafeber FP, Bijlsma JW. Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study. Ann Rheum Dis 2011, 70:1099-1103. 10.1136/ard.2010.137943, 21406458.
11. Markatseli TE, Voulgari PV, Alamanos Y, Drosos AA. Prognostic factors of radiological damage in rheumatoid arthritis: a 10-year retrospective study. J Rheumatol 2011, 38:44-52. 10.3899/jrheum.100514, 20952476.
12. van Tuyl LH, Boers M, Lems WF, Landewe RB, Han H, van der Linden S, van de Laar M, Westhovens R, van Denderen JC, Westedt ML, Peeters AJ, Jacobs P, Huizinga TW, van de Brink H, Dijkmans BA, Voskuyl AE. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis 2010, 69:807-812. 10.1136/ard.2009.108027, 19451137.
13. Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, Hensor E, Wakefield RJ, O'Connor PJ, Emery P. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008, 58:2958-2967. 10.1002/art.23945, 18821687.
14. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, Wakefield RJ, O'Connor PJ, Emery P. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006, 54:3761-3773. 10.1002/art.22190, 17133543.
15. Hetland ML, Ejbjerg BJ, Horslev-Petersen K, Jacobsen S, Vestergaard A, Jurik AG, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS, Tarp U, Skjodt H, Pedersen JK, Majgaard O, Svendsen AJ, Ellingsen T, Lindegaard HM, Christensen AF, Vallo J, Torfing T, Narvestad E, Thomsen HS, Ostergaard M, . CIMESTRA study group MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2 year randomized controlled trial (CIMESTRA). Ann Rheum Dis 2009, 68:384-390. 10.1136/ard.2008.088245, 18388160, CIMESTRA study group.
16. Hetland ML, Stengaard-Pedersen K, Junker P, Ostergaard M, Ejbjerg BJ, Jacobsen S, Lottenburger T, Hansen I, Tarp U, Andersen LS, Svendsen A, Pedersen JK, Lauridsen UB, Ellingsen T, Lindegaard H, Podenphant J, Vestergaard A, Jurik AG, Horslev-Petersen K. Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Ann Rheum Dis 2010, 69:1789-1795. 10.1136/ard.2009.125534, 20444751.
17. Davis JM, Knutson KL, Strausbauch MA, Crowson CS, Therneau TM, Wettstein PJ, Matteson EL, Gabriel SE. Analysis of complex biomarkers for human immune-mediated disorders based on cytokine responsiveness of peripheral blood cells. J Immunol 2010, 184:7297-7304. 10.4049/jimmunol.0904180, 2882518, 20495063.
18. Davis JM, Knutson KL, Strausbauch MA, Crowson CS, Therneau TM, Wettstein PJ, Roger VL, Matteson EL, Gabriel SE. A signature of aberrant immune responsiveness identifies myocardial dysfunction in rheumatoid arthritis. Arthritis Rheum 2011, 63:1497-1506.
19. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van der Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48. 10.1002/art.1780380107, 7818570.
20. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980, 23:137-145. 10.1002/art.1780230202, 7362664.
21. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982, 9:789-793.
22. McHorney CA, Ware JE, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994, 32:40-66. 10.1097/00005650-199401000-00004, 8277801.
23. McHorney CA, Ware JE, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993, 31:247-263. 10.1097/00005650-199303000-00006, 8450681.
24. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000, 27:261-263.
25. van der Heijde DMA, van Riel PL, Koster AM, van 't Hof MA, van Rijswijk MH, van der Putte LB. Biannual radiographic assessment of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992, 35:26-34. 10.1002/art.1780350105, 1731813.
26. Smolen JS, Aletaha D, Grisar JC, Stamm TA, Sharp JT. Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. Ann Rheum Dis 2010, 69:1058-1064. 10.1136/ard.2009.114652, 19717399.
27. Johannsen E, Kaye KM. Epstein-Barr virus (infectious mononucleosis, Epstein-Barr virus-associated malignant diseases, and other diseases. Principles and Practice of Infectious Diseases 2009, 1989-2010. Philadelphia, PA: Churchill Livingstone, Mandell GL, Bennett JE, Dolin R, 7.
28. Crumpacker CS, Zhang JL. Cytomegalovirus. Principles and Practice of Infectious Diseases 2009, 1971-1987. Philadelphia, PA: Churchill Livingstone, Mandell GL, Bennett JE, Dolin R, 7.
29. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 2010, 20:202-213. 10.1002/rmv.655, 20564615.
30. Jackson SE, Mason GM, Wills MR. Human cytomegalovirus immunity and immune evasion. Virus Res 2011, 157:151-160. 10.1016/j.virusres.2010.10.031, 21056604.
31. Vossen MT, Westerhout EM, Soderberg-Naucler C, Wiertz EJ. Viral immune evasion: a masterpiece of evolution. Immunogenetics 2002, 54:527-542. 10.1007/s00251-002-0493-1, 12439615.
32. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, Sleath PR, Grabstein KH, Hosken NA, Kern F, Nelson JA, Picker LJ. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005, 202:673-685. 10.1084/jem.20050882, 2212883, 16147978.
33. Alspaugh MA, Henle G, Lennette ET, Henle W. Elevated levels of antibodies to Epstein-Barr virus antigens in sera and synovial fluids of patients with rheumatoid arthritis. J Clin Invest 1981, 67:1134-1140. 10.1172/JCI110127, 370674, 6259211.
34. Catalano MA, Carson DA, Slovin SF, Richman DD, Vaughan JH. Antibodies to Epstein-Barr virus-determined antigens in normal subjects and in patients with seropositive rheumatoid arthritis. Proc Natl Acad Sci USA 1979, 76:5825-5828. 10.1073/pnas.76.11.5825, 411744, 230491.
35. Elson CJ, Crawford DH, Bucknall RC, Allen C, Thompson JL, Epstein MA, Hall ND, Bacon PA. Infection with E.B. virus and rheumatoid arthritis. Lancet 1979, 1:105.
36. Ferrell PB, Aitcheson CT, Pearson GR, Tan EM. Seroepidemiological study of relationships between Epstein-Barr virus and rheumatoid arthritis. J Clin Invest 1981, 67:681-687. 10.1172/JCI110083, 370617, 6259207.
37. Tsuchiya N, Murayama T, Yoshinoya S, Matsuta K, Shiota M, Furukawa T, Ito K. Antibodies to human cytomegalovirus 65-kilodalton Fc binding protein in rheumatoid arthritis: idiotypic mimicry hypothesis of rheumatoid factor production. Autoimmunity 1993, 15:39-48. 10.3109/08916939309004837, 8218829.
38. Venables PJ, Ross MG, Charles PJ, Melsom RD, Griffiths PD, Maini RN. A seroepidemiological study of cytomegalovirus and Epstein-Barr virus in rheumatoid arthritis and sicca syndrome. Ann Rheum Dis 1985, 44:742-746. 10.1136/ard.44.11.742, 1001762, 2998290.
39. Einsele H, Steidle M, Muller CA, Fritz P, Zacher J, Schmidt H, Saal JG. Demonstration of cytomegalovirus (CMV) DNA and anti-CMV response in the synovial membrane and serum of patients with rheumatoid arthritis. J Rheumatol 1992, 19:677-681.
40. Mehraein Y, Lennerz C, Ehlhardt S, Remberger K, Ojak A, Zang KD. Latent Epstein-Barr virus (EBV) infection and cytomegalovirus (CMV) infection in synovial tissue of autoimmune chronic arthritis determined by RNA- and DNA-in situ hybridization. Mod Pathol 2004, 17:781-789. 10.1038/modpathol.3800119, 15044921.
41. Mousavi-Jazi M, Bostrom L, Lovmark C, Linde A, Brytting M, Sundqvist VA. Infrequent detection of cytomegalovirus and Epstein-Barr virus DNA in synovial membrane of patients with rheumatoid arthritis. J Rheumatol 1998, 25:623-628.
42. Murayama T, Jisaki F, Ayata M, Sakamuro D, Hironaka T, Hirai K, Tsuchiya N, Ito K, Furukawa T. Cytomegalovirus genomes demonstrated by polymerase chain reaction in synovial fluid from rheumatoid arthritis patients. Clin Exp Rheumatol 1992, 10:161-164.
43. Stahl HD, Hubner B, Seidl B, Liebert UG, van der Heijden IM, Wilbrink B, Kraan MC, Emmrich F, Tak PP. Detection of multiple viral DNA species in synovial tissue and fluid of patients with early arthritis. Ann Rheum Dis 2000, 59:342-346. 10.1136/ard.59.5.342, 1753147, 10784515.
44. Takeda T, Mizugaki Y, Matsubara L, Imai S, Koike T, Takada K. Lytic Epstein-Barr virus infection in the synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 2000, 43:1218-1225. 10.1002/1529-0131(200006)43:6<1218::AID-ANR4>3.0.CO;2-2, 10857780.
45. Hamerman D, Gresser I, Smith C. Isolation of cytomegalovirus from synovial cells of a patient with rheumatoid arthritis. J Rheumatol 1982, 9:658-664.
46. Saal JG, Krimmel M, Steidle M, Gerneth F, Wagner S, Fritz P, Koch S, Zacher J, Sell S, Einsele H, Muller CA. Synovial Epstein-Barr virus infection increases the risk of rheumatoid arthritis in individuals with the shared HLA-DR4 epitope. Arthritis Rheum 1999, 42:1485-1496. 10.1002/1529-0131(199907)42:7<1485::AID-ANR24>3.0.CO;2-7, 10403278.
47. Yarilin DA, Valiando J, Posnett DN. A mouse herpesvirus induces relapse of experimental autoimmune arthritis by infection of the inflammatory target tissue. J Immunol 2004, 173:5238-5246.
48. Pyzik M, Gendron-Pontbriand EM, Fodil-Cornu N, Vidal SM. Self or nonself? That is the question: sensing of cytomegalovirus infection by innate immune receptors. Mamm Genome 2011, 22:6-18. 10.1007/s00335-010-9286-2, 20882286.
49. Compton T, Kurt-Jones EA, Boehme KW, Belko J, Latz E, Golenbock DT, Finberg RW. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol 2003, 77:4588-4596. 10.1128/JVI.77.8.4588-4596.2003, 152130, 12663765.
50. Delale T, Paquin A, Asselin-Paturel C, Dalod M, Brizard G, Bates EE, Kastner P, Chan S, Akira S, Vicari A, Biron CA, Trinchieri G, Briere F. MyD88-dependent and -independent murine cytomegalovirus sensing for IFN-alpha release and initiation of immune responses in vivo. J Immunol 2005, 175:6723-6732.
51. Edelmann KH, Richardson-Burns S, Alexopoulou L, Tyler KL, Flavell RA, Oldstone MB. Does Toll-like receptor 3 play a biological role in virus infections?. Virology 2004, 322:231-238. 10.1016/j.virol.2004.01.033, 15110521.
52. Krug A, French AR, Barchet W, Fischer JA, Dzionek A, Pingel JT, Orihuela MM, Akira S, Yokoyama WM, Colonna M. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 2004, 21:107-119. 10.1016/j.immuni.2004.06.007, 15345224.
53. Tabeta K, Georgel P, Janssen E, Du X, Hoebe K, Crozat K, Mudd S, Shamel L, Sovath S, Goode J, Alexopoulou L, Flavell RA, Beutler B. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci USA 2004, 101:3516-3521. 10.1073/pnas.0400525101, 373494, 14993594.
54. Zucchini N, Bessou G, Traub S, Robbins SH, Uematsu S, Akira S, Alexopoulou L, Dalod M. Cutting edge: overlapping functions of TLR7 and TLR9 for innate defense against a herpesvirus infection. J Immunol 2008, 180:5799-5803.
55. Michaud F, Coulombe F, Gaudreault E, Kriz J, Gosselin J. Involvement of TLR2 in recognition of acute gammaherpesvirus-68 infection. PLoS One 2010, 5:e13742. 10.1371/journal.pone.0013742, 2966425, 21060793.
56. Fiola S, Gosselin D, Takada K, Gosselin J. TLR9 contributes to the recognition of EBV by primary monocytes and plasmacytoid dendritic cells. J Immunol 2010, 185:3620-3631. 10.4049/jimmunol.0903736, 20713890.
57. Iwakiri D, Zhou L, Samanta M, Matsumoto M, Ebihara T, Seya T, Imai S, Fujieda M, Kawa K, Takada K. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J Exp Med 2009, 206:2091-2099. 10.1084/jem.20081761, 2757889, 19720839.
58. Ariza ME, Glaser R, Kaumaya PT, Jones C, Williams MV. The EBV-encoded dUTPase activates NF-kappa B through the TLR2 and MyD88-dependent signaling pathway. J Immunol 2009, 182:851-859.
59. Guggemoos S, Hangel D, Hamm S, Heit A, Bauer S, Adler H. TLR9 contributes to antiviral immunity during gammaherpesvirus infection. J Immunol 2008, 180:438-443.
60. Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, Waggoner L, Vanaja SK, Monks BG, Ganesan S, Latz E, Hornung V, Vogel SN, Szomolanyi-Tsuda E, Fitzgerald KA. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol 2010, 11:395-402. 10.1038/ni.1864, 2887480, 20351692.
61. DeFilippis VR, Alvarado D, Sali T, Rothenburg S, Fruh K. Human cytomegalovirus induces the interferon response via the DNA sensor ZBP1. J Virol 2010, 84:585-598. 10.1128/JVI.01748-09, 2798427, 19846511.
62. Takaoka A, Wang Z, Choi MK, Yanai H, Negishi H, Ban T, Lu Y, Miyagishi M, Kodama T, Honda K, Ohba Y, Taniguchi T. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007, 448:501-505. 10.1038/nature06013, 17618271.
63. Wang Z, Choi MK, Ban T, Yanai H, Negishi H, Lu Y, Tamura T, Takaoka A, Nishikura K, Taniguchi T. Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing molecules. Proc Natl Acad Sci USA 2008, 105:5477-5482. 10.1073/pnas.0801295105, 2291118, 18375758.
64. Fasth AE, Snir O, Johansson AA, Nordmark B, Rahbar A, Af Klint E, Bjorkstrom NK, Ulfgren AK, van Vollenhoven RF, Malmstrom V, Trollmo C. Skewed distribution of proinflammatory CD4+CD28null T cells in rheumatoid arthritis. Arthritis Res Ther 2007, 9:R87. 10.1186/ar2286, 2212553, 17825098.
65. Martens PB, Goronzy JJ, Schaid D, Weyand CM. Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arthritis Rheum 1997, 40:1106-1114. 10.1002/art.1780400615, 9182921.
66. Thewissen M, Somers V, Hellings N, Fraussen J, Damoiseaux J, Stinissen P. CD4+CD28null T cells in autoimmune disease: pathogenic features and decreased susceptibility to immunoregulation. J Immunol 2007, 179:6514-6523.
67. Morgan MD, Pachnio A, Begum J, Roberts D, Rasmussen N, Neil DA, Bajema I, Savage CO, Moss PA, Harper L. CD4+CD28- T-cell expansion in Wegener's granulomatosis is driven by latent CMV and is associated with an increased risk of infection and mortality. Arthritis Rheum 2011,
68. Hooper M, Kallas EG, Coffin D, Campbell D, Evans TG, Looney RJ. Cytomegalovirus seropositivity is associated with the expansion of CD4+CD28- and CD8+CD28- T cells in rheumatoid arthritis. J Rheumatol 1999, 26:1452-1457.
69. Amyes E, Hatton C, Montamat-Sicotte D, Gudgeon N, Rickinson AB, McMichael AJ, Callan MF. Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection. J Exp Med 2003, 198:903-911. 10.1084/jem.20022058, 2194204, 12975456.
70. van Bergen J, Kooy-Winkelaar EM, van Dongen H, van Gaalen FA, Thompson A, Huizinga TW, Feltkamp MC, Toes RE, Koning F. Functional killer Ig-like receptors on human memory CD4+ T cells specific for cytomegalovirus. J Immunol 2009, 182:4175-4182. 10.4049/jimmunol.0800455, 19299715.
71. Fritsch RD, Shen X, Sims GP, Hathcock KS, Hodes RJ, Lipsky PE. Stepwise differentiation of CD4 memory T cells defined by expression of CCR7 and CD27. J Immunol 2005, 175:6489-6497.
72. Almanzar G, Schwaiger S, Jenewein B, Keller M, Herndler-Brandstetter D, Wurzner R, Schonitzer D, Grubeck-Loebenstein B. Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. J Virol 2005, 79:3675-3683. 10.1128/JVI.79.6.3675-3683.2005, 1075718, 15731261.
73. Lunemann JD, Frey O, Eidner T, Baier M, Roberts S, Sashihara J, Volkmer R, Cohen JI, Hein G, Kamradt T, Munz C. Increased frequency of EBV-specific effector memory CD8+ T cells correlates with higher viral load in rheumatoid arthritis. J Immunol 2008, 181:991-1000. 2570434, 18606650.
74. Fazou C, Yang H, McMichael AJ, Callan MF. Epitope specificity of clonally expanded populations of CD8+ T cells found within the joints of patients with inflammatory arthritis. Arthritis Rheum 2001, 44:2038-2045. 10.1002/1529-0131(200109)44:9<2038::AID-ART353>3.0.CO;2-1, 11592365.
75. Tan LC, Mowat AG, Fazou C, Rostron T, Roskell H, Dunbar PR, Tournay C, Romagne F, Peyrat MA, Houssaint E, Bonneville M, Rickinson AB, McMichael AJ, Callan MF. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes. Arthritis Res 2000, 2:154-164. 10.1186/ar80, 17809, 11062606.
76. David-Ameline J, Lim A, Davodeau F, Peyrat MA, Berthelot JM, Semana G, Pannetier C, Gaschet J, Vie H, Even J, Bonneville M. Selection of T cells reactive against autologous B lymphoblastoid cells during chronic rheumatoid arthritis. J Immunol 1996, 157:4697-4706.
77. Gerli R, Schillaci G, Giordano A, Bocci EB, Bistoni O, Vaudo G, Marchesi S, Pirro M, Ragni F, Shoenfeld Y, Mannarino E. CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 2004, 109:2744-2748. 10.1161/01.CIR.0000131450.66017.B3, 15159291.
78. Gilani SR, Vuga LJ, Lindell KO, Gibson KF, Xue J, Kaminski N, Valentine VG, Lindsay EK, George MP, Steele C, Duncan SR. CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS One 2010, 5:e8959. 10.1371/journal.pone.0008959, 2813297, 20126467.
79. Posnett DN. Herpesviruses and autoimmunity. Curr Opin Investig Drugs 2008, 9:505-514.
80. Brennan FM, Smith NM, Owen S, Li C, Amjadi P, Green P, Andersson A, Palfreeman AC, Hillyer P, Foey A, Beech JT, Feldmann M. Resting CD4+ effector memory T cells are precursors of bystander-activated effectors: a surrogate model of rheumatoid arthritis synovial T-cell function. Arthritis Res Ther 2008, 10:R36. 10.1186/ar2390, 2452984, 18353171.
81. Di Genova G, Savelyeva N, Suchacki A, Thirdborough SM, Stevenson FK. Bystander stimulation of activated CD4+ T cells of unrelated specificity following a booster vaccination with tetanus toxoid. Eur J Immunol 2010, 40:976-985. 10.1002/eji.200940017, 20104490.
82. Heller KN, Gurer C, Munz C. Virus-specific CD4+ T cells: ready for direct attack. J Exp Med 2006, 203:805-808. 10.1084/jem.20060215, 2118265, 16549599.
83. Haigh TA, Lin X, Jia H, Hui EP, Chan AT, Rickinson AB, Taylor GS. EBV latent membrane proteins (LMPs) 1 and 2 as immunotherapeutic targets: LMP-specific CD4+ cytotoxic T cell recognition of EBV-transformed B cell lines. J Immunol 2008, 180:1643-1654.
84. Moss P. The emerging role of cytomegalovirus in driving immune senescence: a novel therapeutic opportunity for improving health in the elderly. Curr Opin Immunol 2010, 22:529-534. 10.1016/j.coi.2010.07.001, 20685099.
85. van de Berg PJ, Griffiths SJ, Yong SL, Macaulay R, Bemelman FJ, Jackson S, Henson SM, ten Berge IJ, Akbar AN, van Lier RA. Cytomegalovirus infection reduces telomere length of the circulating T cell pool. J Immunol 2010, 184:3417-3423. 10.4049/jimmunol.0903442, 20176738.
86. Spyridopoulos I, Hoffmann J, Aicher A, Brummendorf TH, Doerr HW, Zeiher AM, Dimmeler S. Accelerated telomere shortening in leukocyte subpopulations of patients with coronary heart disease: role of cytomegalovirus seropositivity. Circulation 2009, 120:1364-1372. 10.1161/CIRCULATIONAHA.109.854299, 19770396.
87. Fletcher JM, Vukmanovic-Stejic M, Dunne PJ, Birch KE, Cook JE, Jackson SE, Salmon M, Rustin MH, Akbar AN. Cytomegalovirus-specific CD4+ T cells in healthy carriers are continuously driven to replicative exhaustion. J Immunol 2005, 175:8218-8225.